CTY
City Therapeutics Inc.
There isn't enough reported data to score CTY yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CTY Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Healthy | |
| Healthy |
CTY's profitability, cash flow and balance sheet are currently healthy, but its revenue is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTY PE Valuation
CTY has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CTY Forward outlook
There aren't enough analyst estimates for CTY to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CTY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2020 | $0.00 | $0.00 |
| Q1 2020 | $0.00 | $0.00 |
| Q4 2019 | $0.00 | $0.00 |
| Q3 2019 | $0.00 | $0.00 |
| Q2 2019 | $0.00 | $0.00 |
| Q1 2019 | $0.00 | $0.00 |
| Q4 2018 | $0.00 | $0.00 |
| Q3 2018 | $0.00 | $0.00 |
CTY lost $0.00 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
CTY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2020 | $524M | -74% |
| Q1 2020 | $1.9B | -6.7% |
| Q4 2019 | $2B | -4.8% |
| Q3 2019 | $2B | -5.1% |
| Q2 2019 | $2.1B | -2.4% |
| Q1 2019 | $2.1B | -3.5% |
| Q4 2018 | $2.1B | 0% |
| Q3 2018 | $2.1B | +0.4% |
LLY has the stronger quarterly revenue trend. Revenue is down 74% for CTY versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | 130% | +93 points |
| Q1 2020 | 41% | +3.6 points |
| Q4 2019 | 31% | -1.3 points |
| Q3 2019 | 37% | +3.3 points |
| Q2 2019 | 37% | +6.8 points |
| Q1 2019 | 37% | +7.3 points |
| Q4 2018 | 32% | +4 points |
| Q3 2018 | 33% | +7.2 points |
CTY's operating margin was 130% last quarter, up 93 points from the same quarter a year ago, near the top of its range since 2013.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CTY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2020 | $410M | -25% |
| Q1 2020 | $468M | +5.4% |
| Q4 2019 | $737M | -11% |
| Q3 2019 | $552M | -19% |
| Q2 2019 | $544M | -34% |
| Q1 2019 | $444M | +6.5% |
| Q4 2018 | $831M | +120% |
| Q3 2018 | $679M | +231% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with CTY at up 27%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CTY Total Shares
| Quarter | Spent |
|---|---|
| Q2 2020 | $3M |
| Q1 2020 | $8M |
| Q4 2019 | $1M |
| Q3 2019 | $4M |
| Q2 2019 | $2M |
| Q1 2019 | $9M |
| Q4 2018 | $1M |
| Q3 2018 | $5M |
CTY spent $16M buying back its own shares over the past year, down 5.9% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CTY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | 1.3x | Healthy |
| Q1 2020 | 1.3x | Healthy |
| Q4 2019 | 1.6x | Healthy |
| Q3 2019 | 1.4x | Healthy |
| Q2 2019 | 1.4x | Healthy |
| Q1 2019 | 1.4x | Healthy |
| Q4 2018 | 1.5x | Healthy |
| Q3 2018 | 1.5x | Healthy |
CTY's net debt is about 1.3 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CTY Weekly Momentum
As of the close on Nov 12, 2026: $18.98.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CTY PE vs Healthcare Sector
CTY has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CTY Weekly Moving Averages
As of the close on Nov 12, 2026: $18.98.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CTY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $22.4 | $19.0 | -15% |
It's down 15% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CTY on returns for 2026, with the stronger performance.